基本信息 产品详情 公司简介 推荐产品
网站主页 Cifurtilimab
  • (Cifurtilimab)Biosimilar Reference Antibody-GS40130
  • (Cifurtilimab)Biosimilar Reference Antibody-GS40130

1/2

(Cifurtilimab)Biosimilar Reference Antibody-GS40130 新品

Cifurtilimab
300 100μg 起订
湖北 更新日期:2026-03-12

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

英文名称:
Cifurtilimab
CAS号:
1629760-27-5
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Genetically human
偶联物:
靶点:
TNFRSF5/CD40
免疫原:
TNFRSF5/CD40
亚型:
IgG1 - kappa
验证方法:
(Cifurtilimab)Biosimilar Reference Antibody(GS40130) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40130

Cifurtilimab (SEA-CD40) is an investigational humanized anti-CD40 IgG1 monoclonal antibody developed as an immune-activating therapy for cancer. It functions as a CD40 agonist, designed to directly activate a key receptor on immune cells to enhance the body's anti-tumor immune response. Its proposed mechanisms of action include stimulating antigen-presenting cells (APCs) and B cells, as well as inducing antibody-dependent cellular cytotoxicity (ADCC) against CD40-positive tumor cells. The drug is currently in clinical trials for various solid tumors, including melanoma and non-small cell lung cancer (NSCLC).


Cifurtilimab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

Cifurtilimab相关厂家报价

内容声明
拨打电话 立即询价